Share |

T-Ray Science, Inc. Licenses Lung Cancer Detection Technology From The BC Cancer Agency

November 17, 2010 at 12:38 am

Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) (the “Company” or “T-Ray”) announced today that it has entered into an exclusive licensing agreement with the BC Cancer Agency for rights to a device for the early detection of lung cancer.  T-Ray previously announced it had obtained the rights to the device for skin cancer, all gastrointestinal tract cancers and cervical cancer.

“While our skin cancer detector will be our first device to market, securing the rights to lung cancer detection is important because of the prevalence of lung cancer, which is the number one cause of all cancer deaths,” said Thomas Braun, CEO.  “A lung cancer detector will be our second product to market.”

The lung cancer detection device developed by the BC Cancer Agency has been clinically tested on more than 50 patients with excellent results.  The study was done by the BC Cancer Agency in collaboration with the Lung Centre at Vancouver General Hospital. 

The optical biopsy system, known as the Verisānte™ Core™ series, detects spectral bio-markers for cancer. Today, once a doctor spots a lung lesion, it must be surgically biopsied for a full pathology report to determine if it is malignant. However, the Verisānte™ Core™ device determines with exceptional accuracy if a lesion is malignant or benign. Through this quick and non-invasive verification process, the Verisānte™ Core™ device prevents unnecessary biopsies and the resulting stress and health-care risks and costs that accompany the biopsy procedure.

“It is critically important to have an optical biopsy system such as the Verisānte™ Core™ device to help make informed surgical biopsy decisions, because endoscopists and surgeons do not want to take unnecessary biopsies of lung tissue. For optimum patient health, benign lesions should be left alone,” said Dr. Stephen Lam, a co-inventor of the device.

Leading medical expertise

Dr. Lam, MD, FRCPC, is Professor of Medicine at the University of British Columbia, chair of the Lung Tumour Group and leader of the Lung Cancer Prevention Program at the BC Cancer Agency, and a senior scientist in the Cancer Imaging Department of the BC Cancer Agency’s Research Centre. He is a co-inventor of the award-winning LIFE-Lung, which is being used in more than 150 major medical centres worldwide to detect and localize pre-invasive lung cancers.

Dr. Haishan Zeng, PhD and co-inventor of the Verisānte™ Core™, is a senior scientist at the BC Cancer  Agency’s Research Centre and associate professor of dermatology and skin science at the University of British Columbia. Dr. Zeng is a consultant member of the T-Ray Science product development team.

T-Ray earlier acquired technology from and is collaborating with the world renowned BC Cancer Agency, UBC Department of Dermatology and VGH Skin Care Centre, and will now collaborate with Dr. Lam and

the equally renowned VGH Lung Centre.  Their depth of clinical expertise and capability is key to bringing medical devices through regulatory approval and ultimately to the market so that patients have access to better health-care technologies.

Versatile cancer detection platform

The Verisānte™ Core™ series for lung cancer detection and the Verisānte™ Aura™ series for skin cancer detection utilize a proprietary cancer detection technology platform developed by the BC Cancer Agency while the operating software and probe technology are unique to each device. This exclusive platform technology allows T-Ray to develop and offer a range of cancer detection devices for many of the most common cancers.

Under the terms of the Agreement, T-Ray adds an exclusive worldwide right to use and sublicense the BC Cancer Agency’s patented lung cancer detection technology to its original Licensing Agreement announced in July 2010.  In return, the Company will pay BC Cancer Agency an increased annual royalty and will issue an additional 200,000 stock purchase warrants to BC Cancer Agency.  The warrants shall have a term of five years and an exercise price of $0.18.  The Agreement is subject to regulatory approval by the TSX Venture Exchange.

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company committed to developing innovative systems for the early detection of cancer.     

The Company’s initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements.

Our platform technology is also fully extensible to early detection systems for other types of cancer, including lung, gastro-intestinal, colorectal and cervical cancers.

About the BC Cancer Agency

The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


For further information contact:

T-Ray Science, Inc.
Thomas Braun, President & CEO              
Telephone: 1-877-605-0507


Forward Looking Statements  
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top